BioCentury | Mar 2, 2018
Clinical News

Asana reports Phase Ib data for ASN002 in atopic dermatitis

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from a Phase Ib trial showing that atopic dermatitis candidate ASN002 was well tolerated. The most common adverse events reported were transient, mild headache and nausea. The double-blind,...
BioCentury | Jun 16, 2017
Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of a Phase I/II trial showing that oral ASN002 was well...
BioCentury | Dec 2, 2016
Clinical News

ASN-002: Interim Ph I/IIa data

...patients with nodular BCC in an open-label, Australian Phase I/IIa trial showed that once-weekly intratumoral ASN-002...
...comprising all CRs, at the 3×10 11 virus particle/injection dose. Once-weekly 5×10 10 virus particle/injection ASN-002...
...Ascend Biopharmaceuticals Ltd. , Melbourne, Australia Transgene S.A. (Euronext:TNG), Illkirch, France Product: TG1042 , ASN-002...
BioCentury | Oct 19, 2015
Clinical News

TG1042: Phase I/II started

...of ASN-002 in up to 36 patients prior to surgical tumor excision. Patients will receive ASN-002...
...7 weeks, with no treatment during week 4. Ascend has rights to develop and commercialize ASN-002...
...2013). Ascend Biopharmaceuticals Ltd. , Melbourne, Australia Transgene S.A. (Euronext:TNG), Illkirch, France Product: TG1042 , ASN-002...
BioCentury | Jul 15, 2013
Company News

Ascend Biopharmaceuticals, Transgene deal

...Transgene granted Ascend rights to develop and commercialize TG1042 ( ASN-002 ) to treat basal cell...
...potential indications. Ascend plans to start an Australian Phase I/II trial later this year evaluating TG1042...
BioCentury | Dec 8, 2008
Clinical News

TG1042: Interim Phase II data

...that TG1042 produced 5 complete responses, 5 partial responses and 2 cases of stable disease. TG1042...
...halting development of TG1042 until a partner is secured. Transgene S.A. (Euronext:TNG), Strasbourg, France Product: TG1042...
BioCentury | Apr 7, 2008
Finance

2Q Financial Markets Preview: Longing for normalcy

...of its vaccine candidates: Phase IIb data for TG4010 in non-small cell lung cancer (NSCLC); TG1042...
BioCentury | Mar 19, 2007
Clinical News

TG1042: Phase II started

...receive intra-lesional injections of TG 1042 for 4 months. Transgene S.A. (Euronext:Transgene), Strasbourg, France Product: TG1042...
BioCentury | Oct 16, 2006
Clinical News

Ad-IFNg: Phase II/III start

...Transgene will begin a Phase II/III trial. Transgene S.A. (Euronext:Transgene), Strasbourg, France Product: Ad-IFNg ( TG1042...
BioCentury | Jul 25, 2006
Financial News

Transgene raises EUR 14.3 million

...In the third quarter, Transgene plans to start a pivotal Phase II/III trial of its TG1042...
Items per page:
1 - 10 of 26